Skip to main content

Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales

Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.